Health Canada Approves Skyrizi for Pediatric Plaque Psoriasis
Health Canada approves SKYRIZI® (risankizumab) for children with moderate to severe plaque psoriasis, extending the IL-23 inhibitor into a pediatric population.
Topic
Health Canada
Topic
Topic
Topic
Health Canada approves SKYRIZI® (risankizumab) for children with moderate to severe plaque psoriasis, extending the IL-23 inhibitor into a pediatric population.